Baseline demographic data, clinical, laboratory and MRI parameters between the two groups
| Placebo group (N=12) | Etanercept group (N=19) | |
|---|---|---|
| Baseline | ||
| Age (years) | 54.9 ± 13.6 | 53.0 ± 12.1 |
| Disease duration (years) | 11.9 ± 7.7 | 11.9 ± 6.7 |
| Women/men | 10/2 | 17/2 |
| RF positivity (%) | 66.7 | 78.9 |
| Anti-CCP positivity (%) | 66.7 | 63.2 |
| ANA positivity (%) | 50 | 57.9 |
| Clinical/laboratory parameters | ||
| VAS pain (0−100 mm) | 43.4 ± 20.4 | 59.5 ± 24.1 |
| DAS28 (ESR based) | 4.1 ± 0.75 | 5.0 ± 1.03 |
| HAQ score (1−3) | 0.5 (0.2−0.9) | 0.85 (0.42−1.36) |
| Tender joint count (0−66) | 3.5 (3−6) | 4 (1−12) |
| Swollen joint count (0−68) | 3 (2.2−7.5) | 7 (2−16) |
| ESR (mm/h) | 19.1 ± 9.6 | 28.4 ± 13.6 |
| CRP (mg/dl) | 0.9 (0.3−1.1) | 1.7 (0.7−2.9) |
| MRI parameters | ||
| Synovitis score (0−21) | 6.5 (5.2−9.0) | 13.0 (7.0−14.0) |
| Bone oedema score (0−69) | 5.0 (2.0−15.0) | 15.0 (4.0−22.0) |
| Erosion score (0−230) | 13.0 (7.2−36.5) | 27.0 (16.0−53.0) |
| Tenosynovitis score (0−26) | 6.0 (5.0−7.7) | 8.0 (4.0−12.0) |
| RAMRIS total (0−320) | 24.5 (13.7−61.2) | 59.0 (25.0−90.0) |
Values are medians (ranges) and mean ± SD.
anti-CCP, anti-cyclic-citrullinated peptide antibodies; ANA, antinuclear antibody; CRP, C-reactive protein; DAS28, disease activity score 28-joint assessment; ESR, erythrocyte sedimentation rate; HAQ, Health Assessment Questionnaire; RAMRIS, Rheumatoid Arthritis Magnetic Resonance Imaging Score; RF, rheumatoid factor (positive >20 IU); VAS, visual analogue scale.